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Abstract
Infection with West Nile Virus (WNV) affects an increasing number of countries worldwide. Although most human infections
result in no or mild flu-like symptoms, the elderly and those with a weakened immune system are at higher risk for
developing severe neurological disease. Since its introduction into North America in 1999, WNV has spread across the
continental United States and caused annual outbreaks with a total of 36,000 documented clinical cases and,1,500 deaths.
In recent years, outbreaks of neuroinvasive disease also have been reported in Europe. The WNV strains isolated during
these outbreaks differ from those in North America, as sequencing has revealed that distinct phylogenetic lineages of WNV
concurrently circulate in Europe, which has potential implications for the development of vaccines, therapeutics, and
diagnostic tests. Here, we studied the human antibody response to European WNV strains responsible for outbreaks in Italy
and Greece in 2010, caused by lineage 1 and 2 strains, respectively. The WNV structural proteins were expressed as a series
of overlapping fragments fused to a carrier-protein, and binding of IgG in sera from infected persons was analyzed. The
results demonstrate that, although the humoral immune response to WNV in humans is heterogeneous, several dominant
peptides are recognized.
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Introduction
West Nile Virus (WNV) is a mosquito-borne flavivirus that was
first described in Africa in 1937 and is now endemic to large parts
of the tropical and subtropical world. In its natural cycle, WNV
cycles between mosquitoes and birds but also can be transmitted to
and cause infection and disease in humans and other vertebrate
animal species. Clinical manifestations of WNV infections in
humans range from no symptoms, to a febrile syndrome, to
neuroinvasive disease including meningitis, encephalitis, and acute
flaccid paralysis. The most severe neuroinvasive forms affect ,1%
of the WNV-infected humans, primarily the elderly or immuno-
compromised [1]. The virus reached public attention when it was
introduced into North America in 1999, and since has spread over
the entire continent [2]. Since the mid-1990s, WNV has emerged
in both Eastern and Western Europe, where before it only
sporadically caused mild or limited local outbreaks. In compar-
ison, over the last few years, outbreaks with severe disease have
been reported in Romania, Hungary, Russia, Italy, Former
Yugoslav Republic of Macedonia, and Greece, where the virus
is now considered endemic [3–6]. As an example, almost 200
severe WNV infections with 33 deaths were reported in Greece in
2010 [7]. The rate of severe neurologic disease was similar to the
one observed in the USA [AP, unpublished].
The positive-stranded RNA genome of WNV encodes for the
three structural proteins capsid (C), pre-membrane/membrane
(prM/M) and the envelope (E) protein, as well as seven non-
structural proteins [8]. The C protein lies within the inner core of
the virus and binds to viral RNA to form the nucleocapsid. E is the
major surface glycoprotein on the mature virion and functions in
several critical events during the viral life cycle, including receptor
binding, entry, and endosomal fusion. The small glycoprotein M
(and its precursor prM) acts as a chaperone for E protein folding
and also is displayed on the virion surface, albeit in a location
proximal to the viral membrane [9]. Most WNV isolates are
classified into two major lineages, termed lineage 1 and 2, which
share ,75% identity at the nucleotide and ,94% at the amino
acid level [10]. Unlike the epidemiology in the Americas, where a
lineage 1 WNV strain is exclusively detected, there are several
strains belonging to different lineages that circulate in Europe. Co-
circulation in the same area of different WNV strains belonging to
both lineage 1 (clade 1a) and lineage 2 has been reported in Italy
[3,11–13], and different WNV lineage 2 strains were responsible
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for outbreaks in Greece, Romania, and Russia [4,14]. Co-
circulation of WNV of different lineages must be considered for
the development of vaccines, therapeutics, and diagnostics.
The humoral immune response to a WNV infection in small
animal models is characterized by the appearance of IgM
antibodies after 4 to 7 days, with antigen-specific IgG detectable
shortly after [15]. Both neutralizing IgM and IgG are important
means for controlling the infection and likely limit the viremia that
results in WNV dissemination into the central nervous system
[16,17]. Antibodies against WNV are also detected by immuno-
assays to diagnose infections, however, cross-reactivity with other
circulating flaviviruses can confound diagnosis; thus, functional
assays, such as a neutralization test, or nucleic acid based detection
systems are required to confirm a diagnosis of WNV infection [18–
20].
The human immune response to American WNV infections is
being studied extensively. Epitopes for CD8+ T cells and for
several human monoclonal antibodies have been mapped [21–24].
B cell epitopes also have been identified by screening selected
WNV proteins with sera from birds, rodents and horses, but only
to a limited extent with sera from infected humans [25–28]. In
addition, only few data exist as to the immune responses to newly
emerging European WNV strains.
Herein, we describe a platform to investigate systematically
antibody responses to WNV infections using a series of overlap-
ping protein fragments spanning all structural proteins of the virus.
This technology was used to study the IgG response of humans to
linear B-cell epitopes during WNV outbreaks in Italy and Greece
in 2010, which were caused by WNV strains belonging to lineages
1 and 2, respectively. Our results identify areas of the structural
proteins that are strongly recognized by antibodies.
Results
To investigate antibody responses against WNV during
European outbreaks, we designed a series of overlapping
polypeptide fragments of 30 amino acids in length corresponding
to the structural proteins of the Ita09 strain (Table 1). These were
expressed as GST-fusion proteins in E.coli and purified using
glutathione affinity chromatography (Figure 1A). After analyzing
some of the fusion proteins in an ELISA with human sera,
considerable background was observed secondary to antibody
binding to the GST-only sample (data not shown). Subsequently,
size exclusion chromatography was added as a second isolation
step, which improved purity of the samples and enhanced the
specificity of binding (Figure 1B). Next, the optimal concentra-
tions of the fusion proteins in an ELISA was determined by
coating increasing amounts of the antigen and analyzing sera from
WNV infected individuals. As shown in Figure 2, 2 micrograms
per well of peptide was sufficient for optimal signal from sera
containing either high or low antibody titers. A serum dilution of
1:100 was chosen because more concentrated samples led to an
increase in background binding (data not shown).
Sera from WNV-infected humans (with or without clinical
symptoms) were obtained from Greece, Italy, and the United
States. These sera were tested for reactivity with the panel of fusion
proteins by ELISA (Figure 3 and Figure S1). The structural
proteome represented by the polypeptides clearly contains regions
that were recognized preferentially by antibodies from WNV-
infected individuals. The signals were heterogeneous, i.e. only a
few fragments were bound strongly by most or all positive sera (e.g.
peptide prM58–87). However, all WNV-positive sera showed
binding over the defined background to at least one fragment,
and the vast majority recognized several fragments strongly. In
addition, some regions (e.g. the stretch between fragments E91–120
and E171–200 of the E-protein) displayed marginal reactivity with
serum antibodies. The most antigenic linear epitopes appeared to
fall within the prM/M-protein, where robust signals were detected
in several fragments, most pronounced in M6–35. The capsid-
protein was recognized as well, but the titers were lower compared
to prM/M. Three peptides in the E protein (E71–100, E231–260 and
E371–400) resulted in high signals, whereas others (E11–40, E271–300
Table 1. Amino acid sequences of the fragments used in this
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or E311–340) also were recognized by many sera, albeit with lower
intensity. There were no obvious differences between the samples
from Italy, Greece, and the USA for the binding pattern to the
different peptides or the strength of binding to individual peptides.
Fragments C41–70, prM78–92/M1–15, M66–75/E1–20 and E131–160
were excluded from further analysis, as they were recognized
strongly by non-immune negative sera.
We also assessed whether the heterogeneous antibody responses
observed was a feature of the linear epitopes within our peptide
assay. We incubated the same sera with recombinantly expressed
ectodomain (residues 1–415) of the E protein (New York 1999
Figure 1. Purification and testing of recombinant proteins. A: SDS-PAGE showing crude lysates of protein-expressing bacteria and
purification steps. M, size marker; Lane 1, culture expressing GST (arrowhead); lane 2, culture expressing peptide C41–70 (asterisk); lane 3, peptide C41–
70 after glutathione-affinity-purification; lane 4, peptide C41–70 after gelfiltration. B: ELISA using serum I3 on GST purified only with glutathione
sepharose (white column, 500 ng) or additionally with gel filtration chromatography (black column, 2000 ng). Values are the mean of two
independent experiments (performed in duplicate), error bars represent the standard deviation. Statistical analysis to evaluate the difference between
the two signals was performed by using an unpaired t-test, (asterisks, p,0,001).
doi:10.1371/journal.pone.0066507.g001
Figure 2. Optimizing antibody binding to selected peptides. ELISA plates were coated with increasing amounts of the indicated peptides
fused to GST and incubated with human sera: WNV positive sera I2, I4; G11, G12, G15 and negative serum N5. Values are the mean of two
independent experiments (performed in duplicate), error bars represent the standard deviation.
doi:10.1371/journal.pone.0066507.g002
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Figure 3. Analysis of the binding property of selected recombinant peptides with human sera in an ELISA. 30-mer peptides spanning
the WNV-proteins capsid, prM/M and E, fused to GST, were incubated with human sera from outbreaks in Italy (I1-8), Greece (G1–G15) and USA (US1-
2). Those peptides displaying signals with an OD .0,5 are shown (the total number of peptides is shown in Figure S1).Values represent the
absorption over cut-off (mean of four negative sera plus two standard deviations) and are derived from at least two independent experiments
(performed in duplicate). Error bars represent the standard deviation. The background (binding of the serum to GST) was subtracted.
doi:10.1371/journal.pone.0066507.g003
Antibodies to European WNV
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e66507
strain, lineage 1), which showed the correct tertiary structure
folding, as assayed by a panel of conformational-sensitive
monoclonal antibodies and X-ray crystallography [29,30]. Similar
to the results obtained with the peptides, antibody titers varied
substantially among the different sera (Figure 4); hence differ-
ences in IgG levels against structural proteins are intrinsic to
human WNV infections and not restricted to linear peptide
epitopes. Some sera (e.g. US1, G7) showed low or moderate
binding to peptides spanning the E protein but bound strongly to
the recombinant E-ectodomain, suggesting they recognized more
complex structural epitopes, as has been described for some anti-
WNV human monoclonal antibodies [31]. Although the values
obtained with the two types of antigens are not directly
comparable, this suggests that some individuals produce antibodies
that recognize structurally discontinuous epitopes on E, which are
not displayed by our peptide fragments.
To investigate the contribution of antibodies against the
peptides to the overall antibody response against the E protein,
competition experiments were carried out. To this end, sera were
incubated with the fusion proteins displaying peptides E71–100,
E231–260 or E371–400, before they were tested against the
recombinant ectodomain of the E protein. GST-only was used
as a control-competitor. As shown in Figure 5, a clear
competition for binding was observed in some but not all sera,
again highlighting the heterogeneity of the human humoral
responses to WNV. In serum G1, for example, the reactivity to the
E ectodomain was almost completely lost after pre-incubation with
peptide E71–100, indicating that this linear epitope is a major target
of the anti-E response in that particular patient. Similar results
were obtained for E231–260 with serum G14 and, although less
prominent, with sera G2 and G15.
Discussion
Information on the immune responses of humans against newly
emerging European strains of WNV is still limited, especially when
compared to data available after infections with North American
strains. The WNV epidemic in Europe differs from that in North
America in several aspects, such as pathogenicity in birds and the
vector ecology [32]. Also different WNV strains from distinct
genetic lineages are responsible for the outbreaks in Europe. For
infections with the WNV isolates from North America, immuno-
dominant peptides eliciting T cell responses in humans have been
determined [21,33]. Although epitopes for monoclonal antibody
responses have been mapped [22,29], no systematic peptide
mapping has been performed with sera from infected humans. In
this study, we investigated antibody responses to the structural
proteins of WNV during European outbreaks, which occurred in
Greece and Italy in 2010. By screening overlapping 30-mer
peptides with human sera, areas in the structural proteome were
identified as targets of IgG antibodies, indicating the presence of
several linear B cell epitopes within these peptides.
One major observation was that the antibody profiles against
the peptides corresponding to the structural proteins differed
substantially between individuals. This heterogeneity of binding
can best be explained by the variation in the human immune
response to different epitopes and/or differences in sampling as
serum was collected at different time points after symptoms onset
[34]. Heterogeneity in human antibody responses against WNV
Figure 4. Analysis of binding properties of human sera with recombinant E ectodomain in an ELISA. Sera used in this study were
incubated with the recombinant E-ectodomain protein (lineage 1). Mean values of two independent experiments (performed in duplicate) are shown,
and error bars represent the standard deviation.
doi:10.1371/journal.pone.0066507.g004
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infections also was recently demonstrated by [35] who tested four
different sera on recombinant WNV proteins and obtained four
unique binding patterns. While differences in the HLA class I- and
class II-background are associated with protection or susceptibility
to neuroinvasive WNV disease [36], a direct correlation between
severity of infection and the immune response to specific viral
peptides could not be identified in a screen for CD8+ T cell-
epitopes [21]. Analogously, we could not define a correlation
between IgG responses to specific areas of the WNV-structural
proteome and clinical symptoms (data not shown).
Based on the results, the immunodominant peptides were
distributed throughout in the capsid (peptide C61–90), prM/M
(peptides M6–35 to M46–75), and E (peptides E71–100 and E231–260,
which are in domains I and II, and E371–400 in domain III)
proteins. prM/M protein was the most immunogenic in our
analysis. Every infected individual in the study developed
antibodies against one or several fragments of prM/M, making
it a valuable protein for serologic diagnosis and thus an important
constituent of VLP-based test systems [37]. The immunogenicity
of prM protein in the context of human infection has been
highlighted recently in studies with Dengue virus, a related
flavivirus [38–40]. The region displayed by peptides M6–35 and
M26–55 was shown to elicit Dengue-neutralizing antibodies in mice
[41]. Within the E protein, peptides E71–100, E231–260 and E371–400
appeared immunodominant, and the three sequences were
mapped onto the structure of the E ectodomain (Figure 6). Only
fragment E371–400 is situated in domain III (encompassing parts of
the lateral ridge FG-loop), where dominant epitopes for neutral-
izing antibodies in mice are found [42–44]. This data is consistent
with studies suggesting that the human antibody response against
E is skewed away from DIII and towards less-neutralizing epitopes
in domains I and II [22,29]. Indeed, peptide E71–100, which is
located near or within the fusion loop in domain II of the E
protein, was one of the dominant peptides in the present analysis;
however, fusion loop reactive monoclonal antibodies tend to have
poorly neutralizing activity against lineage 1 strains of WNV
[45,46].
The results obtained with the binding to individual peptides
were confirmed by competition studies between peptides and the
recombinant E-ectodomain. In some sera (G1, G2, G15), which
showed strong binding to only one peptide in the E-protein
(Figure 3), the signal for the E-ectodomain was reduced after pre-
incubation with this peptide. As G1, G2 and G15 recognize the
folded E-ectodomain well (Figure 4), these results indicate that
the linear sequences corresponding to E71–100, E231–260 and E371–
400 are accessible for antibody binding. Using sera that showed
binding to multiple E-peptides in the screen, the competition with
a single peptide did not significantly change binding to the E-
ectodomain (e.g. G8, G11 or G12). However, serum G4 only binds
strongly to E71–100, yet there was no competition with this peptide.
Together with the finding that in sera G2, G14 and G15 there was
still a considerable signal left after competition, the data from the
competition tests confirm that antibodies against tertiary structural
epitopes on the E-ectodomain, not displayed by our peptides, are
generated preferentially during infection in some individuals.
By using sera from a WNV outbreak in Israel, [47] described a
linear B-cell epitope in the E protein, which reacted with some, but
not all WNV positive sera. That epitope, located within E351–380,
only was recognized marginally by the sera from our study.
Differences in the infecting strain (e.g. the Ita09 strain contains the
point mutation A369S within the epitope), in the B cell response
by different populations, or in the methodology (e.g. the EP15
epitope of [47] was used as a tandem peptide fused to a phage
protein) might contribute to the disparity in findings.
Somewhat surprisingly, all humans did not develop robust
antibody responses against the recombinant E protein. Serum I3
Figure 5. Competition of antibody binding between selected peptides and recombinant E-ectodomain. The indicated sera were pre-
incubated with recombinant peptides E71–100, E231–260, E371–400 (all fused to GST) or GST alone, before they were bound to recombinant E-ectodomain
of WNV. Values are derived from at least two independent experiments (performed in duplicate). Error bars represent the standard deviation.
Statistical analysis to evaluate the difference between the signals of the competitor peptide and the control competitor (GST alone) were performed
by using a Mann-Whitney Rank Sum Test (asterisks, p,0,05).
doi:10.1371/journal.pone.0066507.g005
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had low levels of antibodies against the E protein ectodomain or
peptides, although a clear response against prM peptide M6–35 was
observed. One caveat to this analysis is that antibodies by patient
I3 could have been generated against E protein epitopes that are
present exclusively on the icosahedral surface of the intact virion,
which are absent from isolated recombinant E protein or peptides.
Indeed, such quaternary epitopes that localize to the hinge region
between domains I and II on the E protein have been described
for human monoclonal antibodies against WNV and DENV
[31,48–50]. Antibodies against the capsid mainly reflect immune
responses against disrupted virions or apoptotic or necrotic
infected cells in which intracellular contents are released. These
are unlikely to have a protective phenotype, except supporting
antigen presentation by antigen presenting cells.
In summary, we show that several peptides of the capsid, the
prM/M, and the E proteins of WNV are recognized by IgG-
antibodies from humans infected with newly emerging European
strains of WNV. All WNV-positive sera bound strongly to at least
one peptide (corresponding to the lineage 1 amino acid sequence)
and no clear differences were observed between sera obtained
from patients from Greece, Italy or the USA that were infected
with lineage 2 or 1 strains. However, the data reveal substantial
differences between individual sera in the patterns of the proteins
and domains recognized, highlighting the heterogeneity of the
human humoral immune response against WNV, which should be
considered during the development of specific diagnostic tests.
Materials and Methods
Protein Expression and Purification
The sequence coding for amino acids 1–810 of the lineage 1
WNV strain ‘‘Ita09’’ (NCBI Acc#. GU011992) was separated into
40 clones, each coding for 30 amino acid long peptides with an
overlap of 10 amino acids on both sides. The length of overlapping
30 amino acids was chosen to optimally detect long linear epitopes
in combination with fine-mapping of the humoral response. The
DNA fragments were produced in the bacterial expression vector
pEXP1 by ATG: biosynthetics (Freiburg, Germany) and contain
the protein glutathione-S-transferase (GST) from Schistosoma
japonicum fused to the N-terminus. Plasmids were transformed into
the E.coli BL21 strain. Colonies were selected from kanamycin-
containing agar plates, incubated overnight in 20 mL of LB media
at 37uC, and protein expression was induced by IPTG (final
concentration, 1 mM). After 16 h of induction, the bacteria were
harvested by spinning for 20 min at 5.0006g at 4uC. The bacterial
cell pellets were resuspended in lysis buffer (20 mM Tris pH 7,4,
200 mM NaCl, 1 mM EDTA). Lysates were obtained after
sonication followed by three freeze-thaw cycles. Subsequently,
the lysates were clarified by centrifugation (20 min at 15,0006g at
4uC). The supernatant was isolated and stored at –80uC until
usage. Clarified lysates containing the GST-fusion proteins were
purified by Glutathione-sepharose chromatography (Qiagen,
Germany) and analysed by SDS-PAGE. A second purification
using size exclusion chromatography (Sepharose 6FF 26/10, GE
Healthcare) was performed to reduce background binding. The
WNV E protein (ectodomain, amino acids 1–415 of New York
1999 strain) was expressed in E. coli and purified as described
previously [29].
Sera
Serum samples from confirmed WNV-infections were obtained
during outbreaks in Italy and Greece in 2010. The Italian samples
(University of Padova, Italy) were derived from seroprevalence
studies, blood donors or patients with West Nile neuroinvasive
disease. The Greek samples (University of Thessaloniki, Greece)
were from patients with neuroinvasive disease, taken during the
acute phase of illness (3–17 days). In addition, two samples were
obtained from Seracare (USA). None of the patients were
vaccinated against other flaviviruses or had a recent travel history
to other countries endemic for WNV. Patients were 32–83 years
old, and only one was born before the Dengue-outbreak in Greece
in 1927 [18]. WNV-negative samples were from each source and
from the University of Leipzig (Germany). The study was
approved by the Padova University Hospital ethics committee
and all persons provided written consent.
Antibody – Peptide Binding Analysis by ELISA
Nunc polysorb plates (Thermo Scientific, Germany) were
coated in duplicate with 2 micrograms of GST-fusion proteins
or with 100 nanograms of recombinant E ectodomain protein (in
coating buffer (15 mM Na2CO3, 35 mM NaHCO3 pH 9.6)) per
well and were incubated over night at 4uC with gentle agitation.
The plates were then washed three times with 350 microliters per
well of PBS/Tween (0.05%), followed by blocking with 5% non-fat
dry milk powder (200 microliters per well) for 2 h at room
Figure 6. Structure of the E-ectodomain of WNV. The sequences corresponding to the peptides E71–100, E231–260 and E371–400 are highlighted in
color. DI, DII and DIII indicate the respective domains.
doi:10.1371/journal.pone.0066507.g006
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temperature (RT). After a second wash step, the human sera
(dilution 1:100 in 5% non-fat dry milk powder, 100 microliters per
well) were incubated for 1.5 h at RT. The sera were removed by a
third wash step and 100 microliters of the secondary antibody
(1:5000 diluted HRP-conjugated Goat-anti-Human IgG, Fisher
Scientific) was added for 1 h at RT. After washing, the TMB-
substrate (BioLegend, Germany) was added to the wells and the
plate was incubated for 30 min at RT in darkness. To stop the
reaction, 1 M H2SO4 was added, followed by measurement at
450 nm and 520 nm (reference wavelength) in an ELISA Reader
(Infiniti M200, Tecan). The cut-off-values were defined for each
individual antigen by calculating the mean of four negative sera
(derived from Italy, Greece and Germany) and adding two
standard deviations. Competition ELISA was performed as
described above, except that 50 nanograms recombinant E
ectodomain was coated and the sera were pre-incubated with 4
micrograms GST-fusion protein or GST for 45 min at RT.
Supporting Information
Figure S1 Analysis of the binding property of all
recombinant peptides used in the study with human
sera in an ELISA. 30-mer peptides spanning the WNV-proteins
capsid, prM/M and E and a small part of NS1, fused to GST,
were incubated with human sera from outbreaks in Italy (I1-8),
Greece (G1–G15) and USA (US1-2). Values represent the
absorption over cut-off (mean of four negative sera plus two
standard deviations, indicated below the peptide names) and are
derived from at least two independent experiments (performed in
duplicate). Error bars represent the standard deviation. The
background (binding of the serum to GST) was subtracted.
(PDF)
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